WO2024160919 - AGENTS, COMPOSITIONS, AND METHODS FOR SUPPORTING BEHAVIOURAL DEVELOPMENT

National phase entry is expected:
Publication Number WO/2024/160919
Publication Date 08.08.2024
International Application No. PCT/EP2024/052415
International Filing Date 31.01.2024
Title [English] AGENTS, COMPOSITIONS, AND METHODS FOR SUPPORTING BEHAVIOURAL DEVELOPMENT [French] AGENTS, COMPOSITIONS ET PROCÉDÉS DE SOUTIEN DE DÉVELOPPEMENT COMPORTEMENTAL
Applicants ** SOCIÉTÉ DES PRODUITS NESTLÉ S.A. Avenue Nestlé 55 1800 VEVEY, CH
Inventors ** RAJHANS, Purva Ch. des Croix-Rouges 2 1007 LAUSANNE, CH SCHNEIDER, Nora Ch. Des Fontaines-Murée 31 A 1808 Les Monts-de-Corsier, CH HAUSER, Jonas 39, Rue de l'Ale 1003 Lausanne, CH ZHU, Hongtu 104 Tremont circle, Chapel Hill,, North Carolina 27516, US LI, Tengfei 1304 Drew Hill Lane Chapel Hill, North Carolina 27514, US CHO, Seoyoon 1351 Mason Farm Road Apt 215B Chapel Hill, North Carolina 27514, US LIN, Weili 4502 Environ Way Chapel Hill, North Carolina 27517, US
Priority Data 23154263.0  31.01.2023  EP 63/462,621  28.04.2023  US
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 1218
EPO Filing, Examination 4835
Japan Filing 577
South Korea Filing 609
USA Filing, Examination 2635
MasterCard Visa
Total: 9874
Abstract [English] The present invention relates to one or more human milk oligosaccharides (HMOs) for use in supporting behavioural development in a subject, wherein the one or more HMOs comprise or consist of: (a) lacto-N-difucohexaose I (LNDFHI); and/or (b) 2'-fucosyllactose (2'FL), 3- fucosyllactose (3FL), lactodifucotetraose (LDFT), lacto-N-fucopentaose II (LNFPII), lacto-N- fucopentaose I (LNFP-I), lacto-N-fucopentaose III (LNFP-III), lacto-N-difucohexaose I (LND- I), monofucosyl-lacto-N-hexaose III (MFLNH-III), lacto-N-fucopentaose V (LNFP-V), lacto-N- neodifucohexaose (LNnDFH) and lacto-N-fucopentaose VI (LNFP-VI). [French] La présente invention concerne un ou plusieurs oligosaccharides de lait humain (HMO) destinés à être utilisés dans le soutien du développement comportemental chez un sujet, l'HMO ou les HMO comprenant ou consistant en : (a) du lacto-N-difucohexaose I (LNDFHI) ; et/ou (b) du 2'-fucosyllactose (2'FL), du 3-fucosyllactose (3FL), du du lactodifucotétraose (LDFT), du lacto-N-fucopentaose II (LNFPII), du lacto-N-fucopentaose I (LNFP-I), du lacto-N-fucopentaose III (LNFP-III), du lacto-N-difucohexaose I (LND-I), du monofucosyl-lacto-N-hexaose III (MFLNH-III), du lacto-N-fucopentaose V (LNFP-V), du lacto-N-néodifucohexaose (LNnDFH) et du lacto-N-fucopentaose VI (LNFP-VI).